62182-54-1

Basic information

• Product Name: (2S,3S)-3-hydroxy-1,2-Pyrrolidinedicarboxylic acid, 1-(phenylMethyl) ester
• Synonyms: (2S,3S)-1-[(benzyloxy)carbonyl]-3-hydroxypyrrolidine-2-carboxylic acid;Cbz-trans-3-Hydroxy-L-proline
• CAS NO: 62182-54-1
• Molecular Formula: C₁₃H₁₅NO₅
• Molecular Weight: 265.2619
• EINECS: -0
• Mol File: 62182-54-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 486.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.416±0.06 g/cm3(Predicted)
• PKA: 3.67±0.40(Predicted)
• CAS DataBase Reference: (2S,3S)-3-hydroxy-1,2-Pyrrolidinedicarboxylic acid, 1-(phenylMethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3S)-3-hydroxy-1,2-Pyrrolidinedicarboxylic acid, 1-(phenylMethyl) ester(62182-54-1)
• EPA Substance Registry System: (2S,3S)-3-hydroxy-1,2-Pyrrolidinedicarboxylic acid, 1-(phenylMethyl) ester(62182-54-1)

Safety Data

• Hazardous Substances Data: 62182-54-1(Hazardous Substances Data)

Usage

Description

(2S,3S)-3-hydroxy-1,2-Pyrrolidinedicarboxylic acid, 1-(phenylmethyl) ester, also known as (2S,3S)-3-hydroxy-L-proline, is a chemical compound that belongs to the class of pyrrolidine carboxylic acids. It is an important chiral building block in the synthesis of various biologically active molecules and has potential applications in the pharmaceutical and organic synthesis fields.

Uses

Used in Pharmaceutical Industry:
(2S,3S)-3-hydroxy-1,2-Pyrrolidinedicarboxylic acid, 1-(phenylmethyl) ester is used as a chiral building block for the synthesis of drugs targeting the central nervous system. Its unique structure allows for the creation of biologically active molecules with potential therapeutic effects.
Used in Organic Synthesis:
(2S,3S)-3-hydroxy-1,2-Pyrrolidinedicarboxylic acid, 1-(phenylmethyl) ester is used as a key intermediate in the synthesis of complex organic compounds. Its versatility and reactivity make it a valuable component in the development of new chemical entities.
Used in Peptidomimetics Research:
(2S,3S)-3-hydroxy-1,2-Pyrrolidinedicarboxylic acid, 1-(phenylmethyl) ester is studied for its potential as a building block for peptidomimetics, which are compounds that mimic the structure and function of peptides. This research could lead to the development of novel therapeutic agents with improved pharmacological properties.

Upstream product

• 501-53-1 benzyl chloroformate 
• 4298-08-2 trans-3-hydroxy-L-proline 
• 31139-36-3 dibenzyl dicarbonate 

Downstream Products

• 1017576-13-4 N-CBZ-(3S)-3-hydroxprolinamide 
• 412279-18-6 (2S,3S)-3-hydroxypyrrolidin-2-carboxamide 
• 496841-04-4 methyl (2S,3S)-3-hydroxypyrrolidine-2-carboxylate 
• 944270-01-3 C₂₀H₂₁NO₅ 
• 1174654-10-4 3-methoxy-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 
• 441718-01-0 1-benzyloxycarbonyl-(2R)-tert-butyldimethylsilyloxymethyl-(3S)-hydroxypyrrolidine 

Relevant articles and documents

PCSK9 ANTAGONIST COMPOUNDS

Disclosed are compounds of Formula (A), or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula (I) or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

Second basic pKa: An overlooked parameter in predicting phospholipidosis-inducing potential of diamines

In this paper, we present the phospholipidosis-inducing potential (PLIP) of forty fragment-sized diamines derived from N-benzyl-4-(methylamino)piperidine and discuss the relationship between their PLIP and the physicochemical properties. Our results demonstrate that the previously reported methods are not suitable for predicting the PLIP of fragment-sized diamines; the second basic pKa can distinguish PLIP-positive diamines from PLIP-negative diamines more accurately than ClogP or most basic pKa. To the best of our knowledge, this is the first report describing the relationship between PLIP and second basic pKa.

PYRROLOBENZODIAZEPINE COMPOUNDS

The invention relates to pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) of formula (I) and in particular to PBD dimers linked through the C1 position, and PBD monomers linked through the C1 position to aromatic groups, and pharmaceutically acceptable salts the